These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34888676)

  • 41. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
    McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
    Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycemic control and fracture risk in elderly patients with diabetes.
    Conway BN; Long DM; Figaro MK; May ME
    Diabetes Res Clin Pract; 2016 May; 115():47-53. PubMed ID: 27242122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Distance to glycemic goal at the time of treatment intensification in patients with type 2 diabetes mellitus failing metformin monotherapy in the United States.
    Fernandes G; Sawhney B; Hannachi H; Liu J; Wang T; Fu AZ; Iglay K; McNeill A; Rajpathak S
    Curr Med Res Opin; 2020 May; 36(5):741-748. PubMed ID: 31990206
    [No Abstract]   [Full Text] [Related]  

  • 45. Role of Ambulatory Glucose Profile in Precision Medicine in Type 2 Diabetes Mellitus.
    Sidharth S; Aggarwal R; Prakash A
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
    Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM
    Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment Patterns in Patients With Newly Diagnosed Type 2 Diabetes in China: A Retrospective, Longitudinal Database Study.
    Wang C; Gao Y; Zhu L; Huang M; Wu Y; Xuan J
    Clin Ther; 2019 Aug; 41(8):1440-1452. PubMed ID: 31155146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early Glycemic Control and Magnitude of HbA
    Svensson E; Baggesen LM; Johnsen SP; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Thomsen RW
    Diabetes Care; 2017 Jun; 40(6):800-807. PubMed ID: 28404659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.
    Zhou JB; Bai L; Wang Y; Yang JK
    Int J Clin Pract; 2016 Feb; 70(2):132-41. PubMed ID: 26709610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.
    Driessen JH; van Onzenoort HA; Henry RM; Lalmohamed A; van den Bergh JP; Neef C; Leufkens HG; de Vries F
    Bone; 2014 Nov; 68():124-30. PubMed ID: 25093264
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
    Sjöstrand M; Iqbal N; Lu J; Hirshberg B
    Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
    Scheen AJ
    Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
    Cook W; Minervini G; Bryzinski B; Hirshberg B
    Postgrad Med; 2014 Oct; 126(6):19-32. PubMed ID: 25414932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes.
    Wang JS; Hung YJ; Lu YC; Tsai CL; Yang WS; Lee TI; Hsiao YC; Sheu WH
    Diabetes Res Clin Pract; 2018 Apr; 138():119-127. PubMed ID: 29444447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors.
    Shimizu N; Ogawa A; Hayashi A; Shichiri M
    J Diabetes Complications; 2022 Jul; 36(7):108225. PubMed ID: 35690574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T; Stirban A; Terjung A; Esmaeili H; Berk A; Thiemann S; Chilton R; von Eynatten M; Marx N
    Cardiovasc Diabetol; 2017 Jan; 16(1):13. PubMed ID: 28109295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.